Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy-Reference-Cited by-同舟云学术

Discovery of JND3229 as a New EGFRC797S Mutant Inhibitor with In Vivo Monodrug Efficacy

Published:2018-10-08 Issue:11 Volume:9 Page:1123-1127
ISSN:1948-5875
Container-title:ACS Medicinal Chemistry Letters
language:en
Short-container-title:ACS Med. Chem. Lett.

Author:

Lu Xiaoyun¹^ORCID,Zhang Tao²³⁴,Zhu Su-Jie⁵,Xun Qiuju⁶,Tong Lingjiang²,Hu Xianglong¹,Li Yan²,Chan Shingpan¹,Su Yi²,Sun Yiming²,Chen Yi²,Ding Jian²,Yun Cai-Hong⁵^ORCID,Xie Hua²,Ding Ke¹^ORCID

Affiliation:

1. International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Chinese Ministry of Education (MOE), School of Pharmacy, Jinan University, 601 Huangpu Avenue West, Guangzhou 510632, China

2. Division of Anti-Tumor Pharmacology, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zu Chong Zhi Road, Shanghai 201203, China

3. School of Life Science and Technology, ShanghaiTech University, 393 Middle Huaxia Road, Shanghai 201210, China

4. School of Pharmacy, University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, China

5. Department of Biophysics and Peking University Institute of Systems Biomedicine, Peking University Health Science Center, Beijing 100191, China

6. Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences, 190 Kaiyuan Avenue, Guangzhou 510530, China

Funder

Government of Guangdong Province

Jinan University

Natural Science Foundation of Guangdong Province

National Natural Science Foundation of China

Guangzhou City Key Laboratory of Precision Chemical Drug Development, Jinan University

Institutes for Drug Discovery and Development, Chinese Academy of Science

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Drug Discovery,Biochemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.8b00373

Reference26 articles.

1. Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy

3. Erlotinib hydrochloride

4. Afatinib: First Global Approval

5. Olmutinib: First Global Approval

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery of a potent, selective, and orally available EGFR C797S mutant inhibitor (DS06652923) with in vivo antitumor activity;Bioorganic & Medicinal Chemistry;2024-09

2. Targeting Solvent-Front Mutations for Kinase Drug Discovery: From Structural Basis to Design Strategies;Journal of Medicinal Chemistry;2024-08-15

3. Design, synthesis, and antitumor activity evaluation of potent fourth-generation EGFR inhibitors for treatment of Osimertinib resistant non-small cell lung cancer (NSCLC);Bioorganic Chemistry;2024-06

4. Structural Insights into the Binding Mode of a BLU-945 Analog with Wild-Type and Mutant EGFRs;Journal of Computational Biophysics and Chemistry;2024-03-16

5. 4D-QSAR and MIA-QSAR Studies of Aminobenzimidazole Derivatives as Fourth-generation EGFR Inhibitors;Medicinal Chemistry;2024-02